Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	18.3	37	135.7	81.35	186.82
Short-Term Investments	59.54	19.94	-	44.48	3.92
Cash & Short-Term Investments	77.84	56.94	135.7	125.83	190.73
Cash Growth	36.71%	-58.04%	7.85%	-34.03%	-21.67%
Other Current Assets	5.02	5.2	5.38	7.72	13.69
Total Current Assets	82.86	62.14	141.08	133.55	204.42
Net Property, Plant & Equipment	4.96	7.33	9.82	12.51	14.97
Long-Term Investments	-	-	-	-	15.11
Other Long-Term Assets	0.72	0.63	0.63	0.63	0.87
Total Assets	88.53	70.09	151.53	146.69	235.37
Accounts Payable	3.98	2.57	2.52	4.74	3.02
Accrued Expenses	13.53	15.56	16.84	16.04	25.39
Current Portion of Leases	3.73	3.46	3.24	3.14	2.91
Unearned Revenue	-	0.15	1.31	9.21	7.64
Total Current Liabilities	21.23	21.74	23.91	33.13	38.96
Long-Term Leases	1.53	4.92	7.9	9.43	11.55
Other Long-Term Liabilities	12.23	72.41	27.64	0.23	0.13
Total Long-Term Liabilities	13.76	77.33	35.54	9.66	11.68
Total Liabilities	34.99	99.07	59.45	42.79	50.64
Common Stock	0.01	0.01	0.01	0	0
Additional Paid-in Capital	695.27	588.58	578.33	502.61	487.35
Accumulated Other Comprehensive Income	0.47	0.45	0.55	0.4	0.45
Retained Earnings	-642.2	-618.01	-486.8	-399.12	-303.07
Shareholders' Equity	53.55	-28.97	92.08	103.9	184.73
Total Liabilities & Equity	88.53	70.09	151.53	146.69	235.37
Total Debt	5.25	8.38	11.14	12.57	14.46
Net Cash (Debt)	72.59	48.56	124.57	113.25	176.28
Net Cash Growth	49.48%	-61.01%	9.99%	-35.75%	-23.52%
Net Cash Per Share	7.34	7.75	48.59	66.31	110.57
Book Value	53.55	-28.97	92.08	103.9	184.73
Book Value Per Share	5.42	-4.62	35.92	60.84	115.87
Tangible Book Value	53.55	-28.97	92.08	103.9	184.73
Tangible Book Value Per Share	5.42	-4.62	35.92	60.84	115.87

Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q